Current Therapeutic Interventions for COVID-19

Abstract

Severe acute respiratory syndrome coronavirus-2 is an important infectious agent that was first detected in China, causing the pandemic and death of thousands of people. Although the clinic of this disease, called coronavirus disease-19 (COVID-19), is variable, cytokine storm and different mechanisms can cause increased mortality as a result of progressive and serious clinical presentations. Since it belongs to a well-known group of viruses, researchers have gained momentum after the isolation and the identification of the features of the virus. Although specific drugs began to be developed, the first potential candidate drugs were drugs such as broad-spectrum antibiotics, antiviral agents, anti-parasitic agents, and interferon, which were planned to be used with similar indications before pandemic. Trials on all steps such as prophylactic and supporting therapies, as well as care for critically ill patients and vaccine investigation studies are still ongoing. The drugs used in the light of the guidelines were frequently updated and some changes were made as a result of reports on side effects and efficacy evaluations. Especially in some drug combinations, side effects like prolonged QT interval, drug-drug interactions, and restrictions on the use of some drugs in the pediatric age group or pregnancy limit the specific, evidence-based and reliable treatment. Although there are many drugs in the trial phase for COVID-19 treatment, the most promising and most effective drugs are discussed and summarized under the light of national guidelines and clinical evidences with all aspects of the literature.

Pediatri ve COVID-19

“…Sadece düşük oksijen desteğine ihtiyaç duyan pediyatrik hastalar için (sadece nazal kanül gibi) önerilmemektedir. Kortikosteroid uygulaması vaka bazlı olarak hastalık şiddeti ve altta yatan tıbbi duruma göre planlanmalıdır (Arsoy HEM, 2020 ).…”

Temelden Kliniğe COVID-19

“…Sadece düşük oksijen desteğine ihtiyaç duyan pediyatrik hastalar için (sadece nazal kanül gibi) önerilmemektedir. Kortikosteroid uygulaması vaka bazlı olarak hastalık şiddeti ve altta yatan tıbbi duruma göre planlanmalıdır (Arsoy HEM, 2020 ).…”

COVID-19 Hastalarında Potansiyel İmmünolojik Tedaviler

“…IVIG has also been administered as adjuvant therapy for critically ill patients. A blood product purified off mixed plasma of healthy individuals, globulins is the parent component and wealthy in anti-bacterial and anti-viral IgG antibodies (24)(25)(26)(27). IVIG is a pool of IgG from thousands of healthy donors and exposed individual donors to endemic infectious illness, vaccines, and ubiquitous microorganisms contributing to the manufacture of IgG antibodies versus distinct microorganisms and their antigens (28)(29)(30)(31).…”